Dyax Corp. to Present at June 2010 Investor
9th Annual Needham Healthcare Conference
Jefferies 2010 Global Life Sciences Conference
ThinkEquity Mid Year Check-Up on Healthcare Conference
June 02, 2010 07:33 AM Eastern Daylight Time
CAMBRIDGE, Mass.--(EON: Enhanced Online News)--Dyax Corp. (NASDAQ:DYAX), a developer of novel
biotherapeutics for unmet medical needs, announced today that company management of Dyax will present at three
investor conferences in June:
l George Migausky, Executive Vice President and Chief Financial Officer, will present on Wednesday, June 9th
at 9:20 AM (ET) at the 9th Annual Needham Healthcare Conference being held June 9-10th at The New
York Palace Hotel in New York City.
l Gustav Christensen, President and Chief Executive Officer, will present on Thursday, June 10th at 1:00 PM
(ET) at the Jefferies 2010 Global Life Sciences Conference being held June 8-11th at the Grand Hyatt in
New York City.
l George Migausky, Executive Vice President and Chief Financial Officer, will present on Wednesday, June
16th at 4:00 PM (ET) at the ThinkEquity Mid Year Check-Up on Healthcare Conference being held June
16th at the Princeton Club in New York City.
The Dyax presentations will be webcast live and may be accessed by visiting the Investor Relations section of the
company website at www.dyax.com. The webcasts will also be available on the Dyax website for a limited period of
time following the conferences.
Dyax is a fully integrated biopharmaceutical company focused on discovering, developing and commercializing novel
biotherapeutics for unmet medical needs. Dyax utilizes its proprietary drug discovery technology to identify antibody,
small protein and peptide compounds for clinical development. Our lead product, DX-88, has been approved under
the brand name KALBITOR® (ecallantide) in the United States for the treatment of acute attacks of hereditary
angioedema in patients 16 years of age and older.
In addition to its approved commercia